Aptamer Group PLC (AIM:APTA) said its ‘generous’ cash runway would allow “licensing opportunities to evolve and potentially crystalise over this extended period”.
Chairman Dr Adam Hargreaves provided the update ahead of the company’s annual meeting in York later on Friday, noting that the company’s cost-cutting targets have been hit.
In July, the group raised £2.6 million and has landed a contract worth £471,000. It has strengthened partnerships with major pharmaceutical firms, diagnostic companies, and biotech businesses.
Key milestones include collaborations with AstraZeneca on fibrosis treatments, Unilever on a deodorant product nearing human trials, and an Optimer-based delivery system for genetic medicines set for pre-clinical testing.